Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 4/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12745370 | 0.84 | NR1I2 (0.45) | NR1I2CFTRGRIA4PER2CRY1 | |
| SCHEMBL12745368 | 0.74 | NR1I2 (0.42) | NR1I2CFTRPER2CRY1CRY2 | |
| SCHEMBL14845739 | 0.74 | CFTR (0.38) | NR1I2CFTRPER2CRY1CRY2 | |
| SCHEMBL12827355 | 0.72 | HDAC10 (0.39) | NR1I2CFTRPER2CRY1CRY2 | |
| SCHEMBL12745363 | 0.69 | NR1I2 (0.43) | NR1I2CFTRCACNA1B | |
| SCHEMBL15096107 | 0.69 | NR1I2 (0.43) | NR1I2CFTRCACNA1B | |
| SCHEMBL19085762 | 0.69 | CFTR (0.39) | NR1I2CFTR | |
| SCHEMBL14845741 | 0.64 | CFTR (0.41) | NR1I2CFTRMEN1KMT2A | |
| SCHEMBL13365257 | 0.58 | CFTR (0.51) | NR1I2CFTRMEN1KMT2ACACNA1B | |
| SCHEMBL23278438 | 0.58 | CFTR (0.42) | NR1I2CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190076419-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987348-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | NR1I2 491/4885CFTR 1/4885CASR 687/4885 |
| US-20190076419-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | NR1I2 491/4885CFTR 1/4885CASR 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.